KYNB Stock Chart & Stats
$127.90
$0.00(0.00%)
At close: 4:00 PM EDT
$127.90
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$109.00 - $273.00
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
$471.88M
Enterprise Value-$6.04
Total Cash (Recent Filing)$87.24M
Total Debt (Recent Filing)$19.25M
Price to Earnings (P/E)0.2
Beta0.82
Next Earnings
Aug 13, 2026EPS Estimate
-54.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)41.56
Shares Outstanding4,048,112
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$621.00Price Target Upside385.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-239.69
Revenue Forecast (FY)$173.39M
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was $109.00 and its highest was $273.00 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $471.88M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Aug 13, 2026 which is in 7 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on May 11, 2026. The company reported -$64.814 earnings per share for the quarter, missing the consensus estimate of -$57.833 by -$6.981.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -54.89.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,048,112 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of -$64.814 in its last earnings report, missing expectations of -$57.833. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in MX:KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Company Deck
KYNB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress across two key programs (FG-3246/FG-3180 and roxadustat), supportive subgroup efficacy data, validated mitigation of a key ADC safety issue, improved financial discipline with reduced R&D and SG&A, revenue growth, and a cash runway into 2028. Key risks include ongoing net losses, small revenue base, an unresolved biomarker statistical significance that 'just missed' in the IST, residual safety concerns around neutropenia, and reliance on upcoming binary clinical readouts and enrollment execution. On balance, the positives (clinical signals, validated mitigation strategy, constructive FDA feedback on roxadustat, cash runway and expense reductions) outweigh the lowlights, though the company remains dependent on near-term trial execution.View all MX:KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
$621.00
▲(385.54% Upside)